Inovio director receives RSUs and stock options
INOVIO PHARMACEUTICALS, INC. director Roger D. Dansey received new equity compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
INOVIO PHARMACEUTICALS, INC. director Roger D. Dansey received new equity compensation. On May 20, 2026, he was granted 34,200 restricted stock units and 41,800 stock options with a $1.23 exercise price. Both the RSUs and options vest 100% on May 20, 2027 under the 2023 Omnibus Incentive Plan.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock Options | 41,800 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 34,200 | $0.00 | $0.00 |
Footnotes (3)
- F1. This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy.
- F2. Options to vest 100% on May 20, 2027.
- F3. Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027.
Key Figures
Key Terms
Restricted Stock Unit financial
2023 Omnibus Incentive Plan financial
non-employee director compensation policy financial
Common Stock Options financial
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did INO director Roger D. Dansey receive on May 20, 2026?
What are the vesting terms of Roger D. Dansey’s new INO restricted stock units?
What are the key terms of the stock options granted to INO director Roger D. Dansey?
Were Roger D. Dansey’s INO equity awards open-market purchases or compensation grants?
AI-generated analysis. How Rhea-AI works. Not financial advice.